Over 10,000 results
424B4
ABVC
ABVC BioPharma Inc
22 May 24
Prospectus supplement with pricing info
5:00pm
, and the interim analysis of the study is in progress.
Drug: ABV-1601, Major Depression in Cancer Patients, Phase I/II, NCE drug Principal Investigator: Scott … quarter of 2024:
Drug: ABV-1519, Non-Small Cell Lung Cancer treatment, Phase I/II Study in Taiwan, Principal Investigator: Dr. Yung-Hung Luo, M.D
424B3
KRRO
Korro Bio Inc.
22 May 24
Prospectus supplement
4:37pm
be no assurance that RNA editing technologies will not cause undesirable side effects, such as lymphoma, leukemia, or other cancers, or other aberrantly … to the manufacture or distribution of vaccines or medical supplies needed to test or treat patients in a disease outbreak, epidemic or pandemic, this could
424B3
BDRX
Biodexa Pharmaceuticals Plc
22 May 24
Prospectus supplement
4:04pm
with some cancers compared to others. As a result, we may be required to discontinue development of MTX110 for patients with those tumor types … rights are limited to the treatment of brain cancer in humans, administered by convection-enhanced delivery. We received a letter dated June 1, 2020
20-F/A
2022 FY
ETAO
ETAO International Co., Ltd.
22 May 24
Annual report (foreign) (amended)
2:51pm
at various stages (pilot to clinical trials) covering the following diseases: lung/breast cancer, leukemia to type 2 diabetes and alopecia (baldness). We … and to be in compliance with local vaccination and testing policies. While working remotely has proven to be effective to this point, it may eventually inhibit our
424B4
d9kaxp xo1r
22 May 24
Prospectus supplement with pricing info
2:31pm
8-K
EX-99.1
qmjaqv1y7l4637ww
22 May 24
Arbutus to Present Imdusiran Data at EASL Congress 2024
6:00am
S-1
zcaxk cxu5of46rff2
21 May 24
IPO registration
5:29pm
8-K
EX-99.1
cxsa2kz
21 May 24
Entry into a Material Definitive Agreement
5:23pm
6-K
EX-99.1
u616 ls3eh1sdvvzdk9e
21 May 24
BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO Annual Meeting 2024
4:36pm
6-K
EX-99.1
w2um1 ub2c
21 May 24
YS Biopharma Announces Results of Extraordinary General Meeting
4:30pm
424B5
6bhgn6x36bgseurrs
21 May 24
Prospectus supplement for primary offering
12:32pm
6-K
EX-99.1
wglbsb owbe3g
21 May 24
Current report (foreign)
9:00am
S-1
pi3 emy9tqcviolqdnqz
20 May 24
IPO registration
5:04pm
F-3
zj9dugv7
20 May 24
Shelf registration (foreign)
4:32pm
F-1/A
30r8g5bhra9ssi
20 May 24
Registration statement (foreign) (amended)
3:53pm
8-K
EX-99.1
snwd7uhjncu0igbepl
20 May 24
Regulation FD Disclosure
9:25am